Revolux
Stop monitoring. Start treating.
Preserving vision and independence through advanced photobiomodulation, engineered as a Class IIa medical device for the community clinic.
- Session length
- 12 min
- Course
- 9 sessions over 3 weeks
- Form factor
- Handheld binocular
- Supervision
- Clinician-initiated
Treat early
Intervene when it matters most, in the years before irreversible vision loss occurs.
Any room, any time
A portable binocular design that fits standard consulting rooms. No dedicated space, no fixed installation.
Precision dosing
Unlike desktop systems, Revolux guarantees exact source-to-eye geometry for every patient, every time.
Inside Revolux
Built part by part around a repeatable dose.
Every element of the platform exists to put a known quantity of light on the retina, the same way, in every clinic. Each part is described here only as far as the published development record allows.
The clinician's side. The two eyecup faces, with the session controls on the unit beneath them.
Renders of the current development prototype. The hardware configuration is approaching design freeze.
Binocular head
Two eyepieces on a hinged bridge. This architecture is what holds the same source-to-eye distance and alignment for every patient, which is what makes the dose repeatable between clinics.
Emitter ring
Red and near-infrared sources arranged in a ring around each aperture. Revolux combines the wavelengths with the strongest clinical effect on mitochondrial function in the retina.
Optical train
The path from each source to the retina, refined with optical engineering partners so that the light arriving at the macula is precise and repeatable rather than approximate.
Control unit
Power and control. Dosage and irradiance are regulated and monitored for the whole of every session, and the soft-start profile is run from here.
Safety interlocks
Positional and physiological gating. Light is delivered only while every criterion is met, and each session is recorded against the clinician who initiated it.
Intelligent delivery
Biological optimisation, with digital intelligence.
Standard devices simply emit light. Revolux controls how, when and whether light is delivered, and records every session it does.
The binocular architecture fixes the distance and alignment between each light source and each eye, so the dose reaching the retina is repeatable from patient to patient and clinic to clinic.
The mechanism
Light that restores cellular energy.
Photobiomodulation uses selected wavelengths of red and near-infrared light to stimulate biological processes in tissue. In the retina, the target is the mitochondria: the structures that produce the energy retinal cells need to function and to clear waste.
In dry AMD those mitochondria become dysfunctional. Revolux is designed to boost and restore their function, supporting the cells rather than replacing them, in a treatment that is non-invasive and non-thermal.
- 1
Light enters the eye
Controlled doses of red and near-infrared light pass through the pupil to the macula.
- 2
Mitochondria absorb it
The light is absorbed inside retinal cells, where mitochondrial function is compromised in dry AMD.
- 3
Energy metabolism is supported
Cellular energy production and repair processes are supported, helping to preserve central vision.
Safety you can audit
Built as a medical device, not a wellness gadget.
Revolux is developed on a foundation of rigorous quality management and regulatory compliance, to meet the demands of modern healthcare environments.
Medical device validation
Developed under an ISO 13485 quality management system, Revolux is engineered to meet Class IIa medical device standards under the EU MDR and UKCA, with validated optical, electrical and biological safety.
Active safety interlocks
Multiple layers of interlocks and adaptive gating ensure light is only delivered when positional and physiological criteria are met. Dosage and irradiance are controlled and monitored for every treatment.
Auditable care
Unlike unsupervised consumer devices, Revolux is designed for accountability. Every session is clinician-initiated and digitally logged, keeping patients inside a managed, traceable care pathway.
- ISO 13485Quality management system
- EU MDRClass IIa, CE-first strategy
- UKCAUK market conformity
- ISO 15004-2Ophthalmic optical safety
- ANSI Z80.36Light hazard protection
- IEC 60601-1Medical electrical safety
- ISO 10993Biocompatibility
You ask, we answer
Frequently asked questions
Answers to the questions optometrists and ophthalmologists ask most about Revolux and what it means for their patients.
Revolux is indicated for adult patients aged 50 and over diagnosed with early or intermediate dry AMD. It allows clinicians to offer active intervention during the years where patients were previously told to simply watch and wait.